About Trevi Therapeutics, Inc.
https://www.trevitherapeutics.comTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.
CEO
Jennifer L. Good
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 105
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Raymond James
Strong Buy
Stifel
Buy
D. Boral Capital
Buy
Clear Street
Buy
Needham
Buy
HC Wainwright & Co.
Buy
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:13.22M
Value:$151.26M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:10.26M
Value:$117.37M
BLACKROCK, INC.
Shares:9.9M
Value:$113.27M
Summary
Showing Top 3 of 173
About Trevi Therapeutics, Inc.
https://www.trevitherapeutics.comTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.92M ▲ | $-11.8M ▲ | 0% | $-0.08 ▲ | $-11.78M ▲ |
| Q2-2025 | $0 | $13.72M ▲ | $-12.3M ▼ | 0% | $-0.09 ▼ | $-12.28M ▼ |
| Q1-2025 | $0 | $11.47M ▼ | $-10.34M ▲ | 0% | $-0.09 ▲ | $-10.31M ▲ |
| Q4-2024 | $0 | $12.21M ▼ | $-11.41M ▲ | 0% | $-0.11 ▲ | $-11.36M ▲ |
| Q3-2024 | $0 | $14.09M | $-13.24M | 0% | $-0.13 | $-13.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $194.93M ▼ | $199.36M ▼ | $9.57M ▼ | $189.79M ▼ |
| Q2-2025 | $203.88M ▲ | $208.34M ▲ | $9.85M ▲ | $198.49M ▲ |
| Q1-2025 | $103.26M ▼ | $107M ▼ | $7.55M ▼ | $99.46M ▼ |
| Q4-2024 | $107.62M ▲ | $110.9M ▲ | $11.26M ▲ | $99.64M ▲ |
| Q3-2024 | $65.49M | $68.91M | $9.94M | $58.97M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.8M ▲ | $-10.88M ▼ | $-50.94M ▼ | $1.63M ▼ | $-60.19M ▼ | $-10.89M ▼ |
| Q2-2025 | $-12.3M ▼ | $-10.1M ▲ | $-2.61M ▲ | $110.39M ▲ | $97.68M ▲ | $-10.1M ▲ |
| Q1-2025 | $-10.34M ▲ | $-13.48M ▼ | $-9.95M ▲ | $8.71M ▼ | $-14.72M ▼ | $-13.48M ▼ |
| Q4-2024 | $-11.41M ▲ | $-9.55M ▲ | $-23.87M ▼ | $51.47M ▲ | $18.05M ▲ | $-9.56M ▼ |
| Q3-2024 | $-13.24M | $-9.56M | $7.67M | $4.98M | $3.09M | $-9.56M |
CEO
Jennifer L. Good
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 105
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Raymond James
Strong Buy
Stifel
Buy
D. Boral Capital
Buy
Clear Street
Buy
Needham
Buy
HC Wainwright & Co.
Buy
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:13.22M
Value:$151.26M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:10.26M
Value:$117.37M
BLACKROCK, INC.
Shares:9.9M
Value:$113.27M
Summary
Showing Top 3 of 173